{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:06:08Z","timestamp":1784531168462,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["114TMU-SHH\\u221229"],"award-info":[{"award-number":["114TMU-SHH\\u221229"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113\\u20132314-B\\u2212038\\u2013021"],"award-info":[{"award-number":["NSTC113\\u20132314-B\\u2212038\\u2013021"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114\\u20132314-B\\u2212038\\u2013089-MY3"],"award-info":[{"award-number":["NSTC 114\\u20132314-B\\u2212038\\u2013089-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113\\u20132311-B\\u2212038\\u2013006-MY3"],"award-info":[{"award-number":["NSTC 113\\u20132311-B\\u2212038\\u2013006-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119699","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:31:15Z","timestamp":1782448275000},"page":"119699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies"],"prefix":"10.1016","volume":"201","author":[{"given":"Li-Tzu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ying","family":"Jhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119699_bib1","doi-asserted-by":"crossref","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.biopha.2026.119699_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/joim.13054","article-title":"Mitochondrial disease in children","volume":"287","author":"Rahman","year":"2020","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119699_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/humu.23723","article-title":"MT-ATP6 mitochondrial disease variants: phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases","volume":"40","author":"Ganetzky","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.biopha.2026.119699_bib4","unstructured":"E.M. Agency, 2023, Withdrawal of application for the marketing authorisation of Lumevoq (lenadogene nolparvovec)."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI136055","article-title":"Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity","volume":"131","author":"Sharma","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"Pt 3","key":"10.1016\/j.biopha.2026.119699_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1042\/bj20021594","article-title":"Mitochondrial threshold effects","volume":"370","author":"Rossignol","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2026.119699_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-444-63233-3.00010-5","article-title":"Mitochondrial diseases","volume":"147","author":"Davis","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.biopha.2026.119699_bib9","article-title":"Use of whole genome sequencing to determine genetic basis of suspected mitochondrial disorders: cohort study","volume":"375","author":"Schon","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200138","article-title":"T.K.d.S.-G. for, Clinical and Genetic Analysis of Patients With TK2 Deficiency","volume":"10","author":"Ceballos","year":"2024","journal-title":"Neurol. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202400023","article-title":"Mitochondrial dysfunction, cause or consequence in neurodegenerative diseases?","volume":"47","author":"Van Acker","year":"2025","journal-title":"Bioessays"},{"issue":"5","key":"10.1016\/j.biopha.2026.119699_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp-2018-317964","article-title":"Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial","volume":"90","author":"Ohsawa","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13023-023-02754-x","article-title":"The evolution of the mitochondrial disease diagnostic odyssey","volume":"18","author":"Thompson","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101293","article-title":"Critically unwell infants and children with mitochondrial disorders diagnosed by ultrarapid genomic sequencing","volume":"27","author":"Ball","year":"2025","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2024.100770","article-title":"The establishment of a molecular diagnostic platform for mitochondrial diseases: From conventional to next-generation sequencing","volume":"48","author":"Tsai","year":"2025","journal-title":"Biomed. J."},{"key":"10.1016\/j.biopha.2026.119699_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1264530","article-title":"The roles of FGF21 and GDF15 in mediating the mitochondrial integrated stress response","volume":"14","author":"Jena","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"10.1016\/j.biopha.2026.119699_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1474-4422(11)70155-7","article-title":"FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study","volume":"10","author":"Suomalainen","year":"2011","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jimd.12307","article-title":"Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease","volume":"44","author":"Lehtonen","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00325","article-title":"Biomarkers of mitochondrial disorders","volume":"21","author":"Shayota","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119699_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/EBC20170114","article-title":"Emerging therapies for mitochondrial diseases","volume":"62","author":"Hirano","year":"2018","journal-title":"Essays Biochem."},{"key":"10.1016\/j.biopha.2026.119699_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mito.2019.02.001","article-title":"Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease","volume":"48","author":"Koga","year":"2019","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.biopha.2026.119699_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.clinthera.2025.02.004","article-title":"PHEMI-Phenylbutyrate in Patients With Lactic Acidosis: A Pilot, Single Arm, Phase I\/II, Open-Label Trial","volume":"47","author":"Marchet","year":"2025","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1567202052773544","article-title":"Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms","volume":"2","author":"Iizuka","year":"2005","journal-title":"Curr. Neurovasc Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119699_bib24","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s00415-018-9057-7","article-title":"Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research","volume":"265","author":"Koga","year":"2018","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119699_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238224","article-title":"L-arginine effects on cerebrovascular reactivity, perfusion and neurovascular coupling in MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) syndrome","volume":"15","author":"Rodan","year":"2020","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib26","first-page":"17","article-title":"Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes","volume":"23","author":"Ikawa","year":"2020","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ene.15626","article-title":"High-dose oral glutamine supplementation reduces elevated glutamate levels in cerebrospinal fluid in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome","volume":"30","author":"Guerrero-Molina","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119699_bib28","first-page":"1127","article-title":"Taurine for Mitochondrial Diseases","volume":"76","author":"Sunada","year":"2024","journal-title":"Brain Nerve"},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.survophthal.2024.10.002","article-title":"Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy","volume":"70","author":"Newman","year":"2025","journal-title":"Surv. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12883-022-02685-3","article-title":"A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (\"KHENERGYC\")","volume":"22","author":"Smeitink","year":"2022","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/brain\/awae308","article-title":"Optimizing rare disorder trials: a phase 1a\/1b randomized study of KL1333 in adults with mitochondrial disease","volume":"148","author":"Pizzamiglio","year":"2025","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181812","article-title":"NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations","volume":"11","author":"Richard","year":"2026","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119699_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-821751-1.00015-4","article-title":"Leigh syndrome","volume":"194","author":"Rahman","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119699_bib34","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/acn3.50846","article-title":"Exploring mTOR inhibition as treatment for mitochondrial disease","volume":"6","author":"Sage-Schwaede","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119699_bib35","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","article-title":"Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial","volume":"101","author":"Karaa","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13023-024-03421-5","article-title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial","volume":"19","author":"Karaa","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119699_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","article-title":"A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism","volume":"23","author":"Reid Thompson","year":"2021","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119699_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101138","article-title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER","volume":"26","author":"Thompson","year":"2024","journal-title":"Genet. Med."},{"key":"10.1016\/j.biopha.2026.119699_bib39","unstructured":"2025, U.Fa.D. Administration, FORZINITY (elamipretide) prescribing information."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ana.25506","article-title":"Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy","volume":"86","author":"Dominguez-Gonzalez","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119699_bib41","unstructured":"2025, U.F.a.D. Administration, KYGEVVI (doxecitine and doxribtimine) prescribing information."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WCO.0000000000001343","article-title":"Clinical trials in Leber hereditary optic neuropathy: outcomes and opportunities","volume":"38","author":"Chen","year":"2025","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119699_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s44321-025-00231-5","article-title":"Clinically translatable mitochondrial gene therapy in muscle using tandem mtZFN architecture","volume":"17","author":"Nash","year":"2025","journal-title":"EMBO Mol. Med."},{"issue":"7817","key":"10.1016\/j.biopha.2026.119699_bib44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41586-020-2477-4","article-title":"A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing","volume":"583","author":"Mok","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119699_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa2415539","article-title":"Mitochondrial donation and preimplantation genetic testing for mtDNA disease","volume":"393","author":"Hyslop","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jimd.12320","article-title":"Seeking impact: global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders","volume":"44","author":"Goldstein","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119699_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s41687-025-00962-6","article-title":"Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectives","volume":"9","author":"Medrano","year":"2025","journal-title":"J. Patient Rep. Outcomes"},{"issue":"6","key":"10.1016\/j.biopha.2026.119699_bib48","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708262","article-title":"mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease","volume":"10","author":"Grady","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119699_bib49","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-026-13794-1","article-title":"Non-invasive biomarkers for diagnosis and monitoring of primary mitochondrial diseases","volume":"273","author":"Arena","year":"2026","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119699_bib50","first-page":"189","article-title":"Three-parent babies: mitochondrial replacement therapies","volume":"24","author":"Farnezi","year":"2020","journal-title":"JBRA Assist. Reprod."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:40:54Z","timestamp":1784529654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S0753332226007353"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119699","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119699"}}